Your browser doesn't support javascript.
loading
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.
Capone, Emily; Iacobelli, Stefano; Sala, Gianluca.
Afiliação
  • Capone E; Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100, Chieti, Italy.
  • Iacobelli S; Center for Advanced Studies and Technology (CAST), Via Polacchi 11, 66100, Chieti, Italy.
  • Sala G; Mediapharma Srl, Via Colonnetta 50/A, 66100, Chieti, Italy.
J Transl Med ; 19(1): 405, 2021 09 26.
Article em En | MEDLINE | ID: mdl-34565385
The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associated protein, while its role in innate immune response upon viral infection remains still to be clarified. Since its discovery dated in early 90 s, a large body of literature has been accumulating highlighting both a prognostic and functional role for LGALS3BP in cancer. Moreover, data from our group and other have strongly suggested that this protein is enriched in cancer-associated extracellular vesicles and may be considered a promising candidate for a targeted therapy in LGALS3BP positive cancers. Here, we extensively reviewed the literature relative to LGALS3BP role in cancer and its potential value as a therapeutic target.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Galectina 3 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Galectina 3 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article